Bispecific antibodies are an emerging cancer treatment that can attach to two targets at once, making them more precise and powerful than traditional antibodies. One arm of the antibody may bind to cancer cells while the other connects T-cells, directing the immune system to attack tumors even when T-cells don’t naturally recognize them. Some bispecifics

Invikafusp alfa is a novel immunotherapy showing promise for advanced colorectal cancer, especially in patients resistant to PD-1 inhibitors. Developed by Marengo Therapeutics, it is a selective dual T-cell agonist that activates and expands specific T cells (Vβ6 and Vβ10), boosting the immune system’s ability to attack cancer cells. Unlike PD-1 inhibitors, which release immune

Triple-negative breast cancer (TNBC) is an aggressive disease that lacks estrogen, progesterone, and HER2 receptors, making standard targeted therapies ineffective. For years, chemotherapy was the primary treatment. Recently, combination approaches have improved outcomes by attacking tumors from multiple angles. One key strategy combines immunotherapy with chemotherapy. TNBC tumors often express PD-L1, helping them evade immune

Combination therapy has transformed treatment for advanced thyroid cancers, especially aggressive anaplastic thyroid cancer (ATC) and radioiodine-refractory differentiated thyroid cancer (DTC). By targeting multiple pathways at once, these approaches overcome resistance and significantly improve patient outcomes compared with traditional single therapies. A major advance is the FDA-approved combination of dabrafenib and trametinib for BRAF V600E–mutated